The US FDA have issued a thinly veiled rebuke to Pfizer CEO Albert Bourla, after his recent comments to Bloomberg News about Covid-19 infections rebounding after treatment with Paxlovid.
Bourla said that, in cases where virus levels rebound, “then you give a second course, like you do with antibiotics, and that’s it,”
In a Paxlovid update on their website, the FDA noted, “there is no evidence of benefit at this time for a longer course of treatment (e.g., 10 days rather than the 5 days recommended in the Provider Fact Sheet for Paxlovid) or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course.”
